Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 14/2002

01-10-2002 | Adis New Drug Profile

Rosuvastatin

A Viewpoint by James D. Best

Author: James D. Best

Published in: Drugs | Issue 14/2002

Login to get access

Excerpt

As a competitive inhibitor of hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase, rosuvastatin will become the sixth cholesterol-lowering drug in the statin class. The issues of safety and effectiveness are critical to its role in the treatment of lipid abnormalities, given the wide availability of other drugs in the same class. …
Metadata
Title
Rosuvastatin
A Viewpoint by James D. Best
Author
James D. Best
Publication date
01-10-2002
Publisher
Springer International Publishing
Published in
Drugs / Issue 14/2002
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.2165/00003495-200262140-00010

Other articles of this Issue 14/2002

Drugs 14/2002 Go to the issue

Adis New Drug Profile

Valdecoxib

Leading Article

The Role of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Antagonists in the Management of Diabetic Complications

Review Article

Camptothecins

Adis New Drug Profile

Rosuvastatin

Adis New Drug Profile

Rosuvastatin

Adis Drug Evaluation

Polyethylene Glycol-Liposomal Doxorubicin